Literature DB >> 2885023

Effect of rifampicin on haem and bilirubin metabolism in man.

K E McColl, G G Thompson, E el Omar, M R Moore, B K Park, M J Brodie.   

Abstract

Haem and bilirubin metabolism was studied in seven healthy volunteers during 4 weeks treatment with rifampicin 600 mg at night. The serum unconjugated bilirubin concentration increased 2-3 fold in the first 24 h of treatment (P less than 0.01) and subsequently fell to below pretreatment values (P less than 0.05) during the third and fourth weeks of rifampicin therapy. In each subject, the activity in leucocytes of delta-aminolaevulinic acid (ALA) synthase increased and that of protoporphyrinogen (proto) oxidase decreased during the first week of therapy. The mean ALA synthase activity was most markedly increased on day 4 being seven-fold its pretreatment value (P less than 0.01), and the mean proto oxidase activity most depressed on day 2 at 50% its pretreatment value (P less than 0.02). There was increased urinary excretion of porphobilinogen (PBG) during the first week of therapy and increased excretion of porphyrins and PBG during the third week of treatment. The increase in ALA synthase activity and haem precursor excretion can be explained by the combination of increased haem demand for haemoprotein induction and partial block in haem synthesis due to reduced proto oxidase activity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2885023      PMCID: PMC1386191          DOI: 10.1111/j.1365-2125.1987.tb03091.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  18 in total

1.  PLASMA BILIRUBIN DETERMINATION IN THE NEWBORN INFANT. A METHODOLOGICAL STUDY WITH SPECIAL REFERENCE TO THE INFLUENCE OF HEMOLYSIS.

Authors:  M MICHAUELSSON; B NOSSLIN; S SJOELIN
Journal:  Pediatrics       Date:  1965-06       Impact factor: 7.124

2.  Hereditary coproporphyria. Demonstration of the abnormalities in haem biosynthesis in peripheral blood.

Authors:  M J Brodie; G G Thompson; M R Moore; A D Beattie; A Goldberg
Journal:  Q J Med       Date:  1977-04

Review 3.  Enzymatic defects in porphyria: an overview.

Authors:  G H Elder
Journal:  Semin Liver Dis       Date:  1982-05       Impact factor: 6.115

Review 4.  Assessment of urinary 6 beta-hydroxycortisol as an in vivo index of mixed-function oxygenase activity.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

5.  Plasma rifampicin assay by an improved solvent extraction technique.

Authors:  J B McConnell; H Smith; M Davis; R Williams
Journal:  Br J Clin Pharmacol       Date:  1979-11       Impact factor: 4.335

6.  Rifampicin and vitamin D metabolism.

Authors:  M J Brodie; A R Boobis; C T Dollery; C J Hillyard; D J Brown; I MacIntyre; B K Park
Journal:  Clin Pharmacol Ther       Date:  1980-06       Impact factor: 6.875

7.  Induction of delta-aminolaevulinic acid synthase in leucocytes of patients on phenytoin therapy--comparison with changes in rat hepatic tissue.

Authors:  K E McColl; M R Moore; G G Thompson; A Goldberg
Journal:  Br J Clin Pharmacol       Date:  1980-04       Impact factor: 4.335

8.  A fluorometric assay for measurement of protoporphyrinogen oxidase activity in mammalian tissue.

Authors:  D A Brenner; J R Bloomer
Journal:  Clin Chim Acta       Date:  1980-01-31       Impact factor: 3.786

9.  The enzymatic defect in variegate prophyria. Studies with human cultured skin fibroblasts.

Authors:  D A Brenner; J R Bloomer
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

10.  Rifampicin-induced porphyria cutanea tarda.

Authors:  J W Millar
Journal:  Br J Dis Chest       Date:  1980-10
View more
  5 in total

1.  Biphasic Effect of Rifampicin on Bilirubin- A Case Report.

Authors:  Manigandan Gopi; Mandalam Subramanian Seshadri
Journal:  J Clin Diagn Res       Date:  2016-04-01

Review 2.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

3.  Comparative Study of the Dose-Dependence of OATP1B Inhibition by Rifampicin Using Probe Drugs and Endogenous Substrates in Healthy Volunteers.

Authors:  Issey Takehara; Takashi Yoshikado; Keiko Ishigame; Daiki Mori; Ken-Ichi Furihata; Nobuaki Watanabe; Osamu Ando; Kazuya Maeda; Yuichi Sugiyama; Hiroyuki Kusuhara
Journal:  Pharm Res       Date:  2018-05-10       Impact factor: 4.200

4.  Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.

Authors:  Anne Schmitt-Hoffmann; Brigitte Roos; Jürgen Maares; Markus Heep; Jochen Spickerman; Erhard Weidekamm; Tom Brown; Michael Roehrle
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.938

Review 5.  Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies.

Authors:  M Strolin Benedetti; P Dostert
Journal:  Environ Health Perspect       Date:  1994-11       Impact factor: 9.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.